Mineralys Therapeutics, Inc. (MLYS) Stock Analysis & Investment Frameworks
Mineralys Therapeutics, Inc. (MLYS) stock analysis on Invetso. Review Mineralys Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Mineralys Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Mineralys Therapeutics, Inc. Key Financial Metrics
- Market Cap: $1.36B
- Revenue: $N/A
- ROE: -63.26%
- ROIC: -64.74%
- Dividend Yield: N/A
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.